BRUSSELS (Reuters) - ThromboGenics' main drug, the eye treatment ocriplasmin, may have a high rate of adverse side effects, the U.S. Food and Drug Administration said that in a preliminary report made available on Tuesday.
via Reuters: Health News Read More Here..
No comments:
Post a Comment